Abstract 15P
Background
Although electrocautery is popularly used for the skin flap preparations at the time of mastectomy, we have been making the skin flap using the tumescent technique for the protects of the wound and skin flap since 2012 in our department. The aim of the study is to examine the differences of the clinical outcomes by between the surgeons (specialist who is familiar with breast surgery vs non-special surgeons).
Methods
166 patients who underwent the reconstruction after 1ststage of mastectomy with the tumescent technique at our hospital from March 2012 to December 2018 were enrolled. Tumescent technique; just before skin incision, we injected the tumescent solusions (200ml of physiological saline, 1mg of adrenaline, 20ml of xylocaine) subcutaneously into the breast and we started the sharp skin incision containing the tumor and around the areola like the spindle shape. If the tumor is close to the skin, we resected the skin just above tumor. We separated between subcutaneous and mammary tissue, and made the skin flap widely using the mechenbaum scissor and the wound retractor for protect the skin cutting edge. The most important things of this technique are to get the viewing field using the wound retractor with light and and the hemostasis exactly using McCannd forceps.
Results
patients characteristics is mean age 47.9 years (25-73 years), BMI is mean 21.1 (16.4-35.4), complication disease are 4 cases of hypertension, 4 cases of diabetes mellitus, 3 cases of radiotherapy previously, we performed surgery for 52 cases of DICS, for 114 cases of the invasive cancer including 10 cases of the axillary lymph node dissections, specialist performed 100 cases of mastectomy, on the other hand non-special surgeons performed 66 cases of mastectomy. Mean operation time is 56 min and 62 min (p = 0.314), there are no significant differences between the weight of the resected tissue and operation time (p = 0.062. Mean blood loss is 54ml each. 49 case (29%) of the mild necrosis of the skin, and 8 cases (4.7%) of hematoma were totally occurred after surgery, There are also no significant differences between specialist and non-special surgeons.
Conclusions
Mastectomy using the tumescent technique is easy and safe for not only specialist but also non-special surgeons.
Clinical trial identification
Editorial acknowledgement
Tissue expander and Inplants were approved for clinical use in Japan in July 2013.Since 2013, the reconstruction after mastectomy has been increasing year by year in Japan.
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
329P - High-level expression of HDAC10 is associated with PD-L1 expression and poor prognosis in patients with non-small cell lung cancer receiving pulmonectomy
Presenter: Xiaomei Liu
Session: Poster display session
Resources:
Abstract
331P - A retrospective analysis of immune checkpoint therapy in patients with non-small cell lung cancer: Focus on thyroid disorder
Presenter: Sawana Ono
Session: Poster display session
Resources:
Abstract
332P - Analyse the association between adverse events (AEs) and survival in patients treated with immune checkpoint inhibitors (ICIs)
Presenter: Chi-yuan Cheng
Session: Poster display session
Resources:
Abstract
333P - Study of searching on efficacy of immune checkpoint inhibitor for the non-small cell lung cancer using FDG-PET/CT and thallium SPECT
Presenter: KAYOKO Kibata
Session: Poster display session
Resources:
Abstract
334P - Incidence and characteristic of adrenal insufficiency due to immune checkpoint inhibitors therapy
Presenter: Daisuke Etoh
Session: Poster display session
Resources:
Abstract
335P - PD-L1 profile of nasopharyngeal cancer patients in Indonesia
Presenter: Handoko Handoko
Session: Poster display session
Resources:
Abstract
336P - Pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for PD-L1-positive advanced non-small cell lung cancer in the real world
Presenter: Jun Sugisaka
Session: Poster display session
Resources:
Abstract
337P - Neutrophil-to-Lymphocyte ratio as a predictive factor for hyperprogressive disease in NSCLC patients treated with immune checkpoint inhibitor
Presenter: Ryo Takahashi
Session: Poster display session
Resources:
Abstract
338P - A new insight into tumour immune-evasion: Crosstalk between cancer stem cells and T regulatory cells
Presenter: Abhishek Dutta
Session: Poster display session
Resources:
Abstract
339TiP - PACIFIC-5: Phase III study of durvalumab after either concurrent or sequential chemoradiotherapy (CRT) in patients with stage III NSCLC
Presenter: Yi-Long Wu
Session: Poster display session
Resources:
Abstract